Implantica AG (OSTO:IMP A SDB) Preferred Dividends : kr0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Implantica AG's preferred dividends for the six months ended in . 20 was kr0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in . 20 was kr0.00 Mil.

Implantica AG Preferred Dividends Historical Data

The historical data trend for Implantica AG's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Preferred Dividends Chart

Implantica AG Annual Data

Trend

Preferred Dividends

Implantica AG Semi-Annual Data

Preferred Dividends

Implantica AG Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Implantica AG (OSTO:IMP A SDB) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Preferred Dividends for the trailing twelve months (TTM) ended in . 20 was kr0.00 Mil.

Implantica AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

8IM1:Germany

Address

Aeulestrasse 45, Vaduz, LIE, 9490

Website

https://www.implantica.com

Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines